United Therapeutics Corporation (UTHR) Earnings
United Therapeutics Corporation is expected to report next earnings on July 29, 2026 (in NaN days), with a consensus EPS estimate of $7.17. UTHR has beaten EPS estimates in 7 of its last 12 reported quarters (average surprise -2.9% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $7.00 | $5.82 | -16.9% | $782M | -2.0% |
| Feb 25, 2026 | $6.78 | $7.70 | +13.6% | $790M | -0.6% |
| Oct 29, 2025 | $6.89 | $7.16 | +3.9% | $800M | -1.9% |
| Jul 30, 2025 | $7.29 | $6.41 | -12.1% | $799M | -0.4% |
| Apr 30, 2025 | $6.29 | $6.63 | +5.4% | $794M | +2.0% |
| Feb 26, 2025 | $6.40 | $6.19 | -3.3% | $736M | +0.2% |
| Oct 30, 2024 | $6.43 | $6.39 | -0.6% | $749M | +3.6% |
| Jul 31, 2024 | $6.40 | $5.85 | -8.6% | $715M | +3.3% |
| May 1, 2024 | $5.65 | $6.17 | +9.2% | $678M | +8.6% |
| Feb 21, 2024 | $4.19 | $4.36 | +4.1% | $615M | +6.7% |
| Nov 1, 2023 | $5.04 | $5.38 | +6.7% | $609M | +3.7% |
| Aug 2, 2023 | $4.51 | $5.24 | +16.2% | $597M | +13.8% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• Martine mentioned two therapeutics in IPF with Tyveso and PAH with Relenopeg having shown better clinical outcomes. • Michael talked about first quarter revenue, Kaideso revenue, Tyveso DPI growth, competitive landscape, underlying demand metrics, Salesforce investments, IPF regulatory filing plans, and commercial goals. • Pat and others discussed details on RALPi development, formulation, and regulatory aspects
Guidance
• Relenopeg and IPF indication expected to put the company on path to more than double revenues over next few years. • Anticipated FDA approvals for Rolenapeg and IPF therapies with launch timelines mentioned. • Plan to double down on relentless innovation, proven experience, and patient obsession for growth
Segment performance
For the first quarter of 2026, total revenue was $782 million. Kaideso total revenue was $458 million. Tyveso DPI contributed 9% year-over-year growth. Relenopeg and Tyveso for IPF are expected to drive revenue growth with revenue run rate going to $4 billion by end of 2027. The inhaled formulation of RALDPI is in stealth mode and foreseen to be a big product
Analyst Q&A
Q: On IPF regulatory filing and JASCADE,
A: Lee discussed bridging strategy for IPF with Tyvesa BPI and Michael talked about JASCADE as proxy for pent-up demand in IPF.
Q: On commercial strategy and peak sales timing,
A: Michael said will provide more granularity as they build out forecast.
Q: On Rwanda PEG DPI,
A: Pat talked about RALPi development progress, re-IND engagement, and Phase 1 study plan.
Q: On REL-PAI development program,
A: Pat talked about timing and pursuing approval with solid dose.
Q: On Rolano Peg BPI formulation,
A: Pat talked about leveraging Mankind's Crystal Carrier IP.
Q: On IPF formulations and regulatory strategy,
A: Michael talked about multiple shots on goal strategy and Lee/Pat talked about regulatory path.
Q: On PHCOPD study,
A: Lee talked about PHCOPD study plans with tricosteal SMI and phases of study